Food Sci Nutr. 2026 Oct 7;14(10):e72428. doi: 10.1002/fsn3.72428. eCollection 2026 Oct.
ABSTRACT
Dyslipidemia is a major risk factor for cardiovascular disease. Studies have shown that vitamin E has therapeutic effects on lipid metabolism; however, findings remain inconsistent. This meta-analysis aims to assess the effectiveness of vitamin E administration on the serum lipid panel in patients with dyslipidemia. A database search through January 2026 was conducted to identify relevant randomized controlled trials (RCTs). Relevant data, including triglycerides (TG), total cholesterol (TC), and low- and high-density lipoprotein cholesterol (LDL-C and HDL-C), were extracted. The overall effect size was estimated using weighted mean differences (WMDs) with 95% confidence intervals (CIs) via a random-effects model. The pooled analysis of 22 RCTs (33 intervention arms) demonstrated that vitamin E significantly lowered TG (WMD: -8.14 mg/dL, p = 0.021) and raised HDL-C (WMD: 1.08 mg/dL, p = 0.037) in patients with dyslipidemia, whereas reductions in TC (WMD: -6.48 mg/dL, p = 0.097) and LDL-C (WMD: -9.06 mg/dL, p = 0.063) were not significant overall. Exploratory subgroup analyses suggested that tocotrienols may exert greater lipid-modifying effects than tocopherols, with potentially larger benefits observed at lower doses, among individuals with more pronounced baseline lipid abnormalities, and during shorter intervention periods. In conclusion, vitamin E supplementation in patients with dyslipidemia shows modest improvements in lipid profiles, mainly lowering TG and increasing HDL-C, with less consistent effects on TC and LDL-C. Tocotrienols may be more effective than tocopherols, suggesting possible isoform-specific effects, but overall clinical impact appears limited and requires further confirmation.
PMID:42846136 | PMC:PMC13643374 | DOI:10.1002/fsn3.72428